Corvus Pharmaceuticals Inc [NASDAQ: CRVS] plunged by -$0.1 during the normal trading session on while it closed the day at $5.65.
Corvus Pharmaceuticals Inc stock has also gained 5.61% of its value over the past 7 days. However, CRVS stock has declined by -4.88% in the 3 months of the year. Over the past six months meanwhile, it has gained 197.37% and gained 5.61% year-on date.
The market cap for CRVS stock reached $363.05 million, with 62.58 million shares outstanding and 50.33 million shares in the current float. Compared to the average trading volume of 1.17M shares, CRVS reached a trading volume of 388883 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Corvus Pharmaceuticals Inc [CRVS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRVS shares is $14.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRVS stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Corvus Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 02, 2025. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on August 18, 2023, representing the official price target for Corvus Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $8, while Jefferies analysts kept a Buy rating on CRVS stock.
The Average True Range (ATR) for Corvus Pharmaceuticals Inc is set at 0.61 The Price to Book ratio for the last quarter was 28.49, with the Price to Cash per share for the same quarter was set at 0.65.
CRVS stock trade performance evaluation
Corvus Pharmaceuticals Inc [CRVS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.61. With this latest performance, CRVS shares dropped by -31.60% in over the last four-week period, additionally plugging by 197.37% over the last 6 months – not to mention a rise of 151.11% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRVS stock in for the last two-week period is set at 41.35, with the RSI for the last a single of trading hit 43.61, and the three-weeks RSI is set at 41.83 for Corvus Pharmaceuticals Inc [CRVS]. The present Moving Average for the last 50 days of trading for this stock 7.63, while it was recorded at 5.74 for the last single week of trading, and 4.30 for the last 200 days.
Corvus Pharmaceuticals Inc [CRVS]: An insightful look at the core fundamentals
Corvus Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.92 and a Current Ratio set at 0.92.
Corvus Pharmaceuticals Inc [CRVS]: Institutional Ownership
There are presently around $44.47%, or 46.34%% of CRVS stock, in the hands of institutional investors. The top three institutional holders of CRVS stocks are: ORBIMED ADVISORS LLC with ownership of 6.94 million shares, which is approximately 14.1596%. SAMLYN CAPITAL, LLC, holding 6.12 million shares of the stock with an approximate value of $$11.14 million in CRVS stocks shares; and SAMLYN CAPITAL, LLC, currently with $$10.86 million in CRVS stock with ownership which is approximately 12.1629%.
